- Home
- ARTW vs SLXN Comparison
ARTW vs SLXN Comparison
Compare ARTW & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTW
- SLXN
- Stock Information
- Founded
- ARTW 1956
- SLXN 2008
- Country
- ARTW United States
- SLXN Israel
- Employees
- ARTW N/A
- SLXN N/A
- Industry
- ARTW Industrial Machinery/Components
- SLXN
- Sector
- ARTW Industrials
- SLXN
- Exchange
- ARTW Nasdaq
- SLXN NYSE
- Market Cap
- ARTW 9.3M
- SLXN 7.3M
- IPO Year
- ARTW N/A
- SLXN N/A
- Fundamental
- Price
- ARTW $2.27
- SLXN $0.80
- Analyst Decision
- ARTW
- SLXN Strong Buy
- Analyst Count
- ARTW 0
- SLXN 1
- Target Price
- ARTW N/A
- SLXN $5.00
- AVG Volume (30 Days)
- ARTW 33.4K
- SLXN 141.1K
- Earning Date
- ARTW 07-15-2025
- SLXN 08-21-2025
- Dividend Yield
- ARTW N/A
- SLXN N/A
- EPS Growth
- ARTW N/A
- SLXN N/A
- EPS
- ARTW 0.14
- SLXN N/A
- Revenue
- ARTW $23,916,932.00
- SLXN N/A
- Revenue This Year
- ARTW N/A
- SLXN N/A
- Revenue Next Year
- ARTW N/A
- SLXN N/A
- P/E Ratio
- ARTW $45.91
- SLXN N/A
- Revenue Growth
- ARTW N/A
- SLXN N/A
- 52 Week Low
- ARTW $1.40
- SLXN $0.58
- 52 Week High
- ARTW $4.15
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- ARTW 67.32
- SLXN N/A
- Support Level
- ARTW $1.88
- SLXN N/A
- Resistance Level
- ARTW $2.42
- SLXN N/A
- Average True Range (ATR)
- ARTW 0.14
- SLXN 0.00
- MACD
- ARTW 0.04
- SLXN 0.00
- Stochastic Oscillator
- ARTW 78.26
- SLXN 0.00
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.